This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

M&A - Boston Scientific - Penumbra

Marlborough, Massachusetts-based Boston Scientific said it will acquire Alameda, California-based Penumbra in a cash and stock transaction that values Penumbra at $374 per share, and give it an enterprise value of about $14.5 billion. Penumbra has mechanical thrombectomy products for use in peripheral vascular procedures to remove blood clots causing blockages in arterial, venous and pulmonary vessels, including the Lightning Bolt and Lightning Flash computer assisted vacuum thrombectomy systems. Both companies are traded on the New York Stock Exchange. The deal is expected to close in 2026. 

Timeline

Parties

Get the inside track, with MLex

With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.


  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

TRY MLEX FREE FOR 14 DAYS

View the parties now

Already a subscriber? Click here to login